Clinical trials: Infectious Disease of Lung
Cystic Fibrosis
A Single Arm 48-Week Follow-on Safety Study to a Core Study Comparing the Efficacy and Tolerability of Tobrineb®/Actitob®/Bramitob® Versus TOBI®
This is a 48-week extension study to CMA-0631-PR-0010 Core Study. Patients who have a positive culture for P. aeruginosa at visit 4 of the first 8-week core study period and/or if deemed appropriate by the Investigators will be…
- Trial name
- CT03Ext (NCT01111383)
- Testing
- tobramycin
- Where
- 20 sites in France, Poland and 1 more
- Volunteers
- 209 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
HIV Infections, Histoplasmosis
A Randomized, Open, Comparative Multicenter Study of Initial Treatment With Intravenous Itraconazole Versus Amphotericin B Followed by Consolidation Treatment With Itraconazole Capsules in Patients With Blastomycosis or Histoplasmosis
To assess the safety of intravenous itraconazole compared to amphotericin B in HIV positive or negative persons with blastomycosis or histoplasmosis.
- Conditions
- HIV Infections, Histoplasmosis, Blastomycosis
- Trial name
- NCT00002159
- Testing
- Itraconazole, Amphotericin B
- Where
- 9 sites in United States
- Volunteers
- 60 people
- Sponsor
- Janssen, LP
Post Acute COVID-19 Syndrome
Digital Health Intervention Based on Artificial Intelligence to Support the Personalized Recovery of Long COVID Patients Affected by Fatigue (AIDA)
The AIDA feasibility study builds upon mental health and technology acceptance theoretical frameworks. It examines the feasibility of a mobile-based digital program to support patients with long covid affected by fatigue.
- Trial name
- AIDA (NCT05483829)
- Testing
- Adhera® Fatigue for Long COVID program
- Where
- Spain
- Volunteers
- 15 people
- Sponsor
- Adhera Health, Inc.
SARS-CoV-2 Infection
A Study to Assess the Efficacy and Safety of XC221 in Patients With COVID-19
The innovative drug XC221 100 mg tablet is designed for the treatment of COVID-19 (SARS-CoV-2 infection). A multicenter, adaptive, randomized, double-blind, placebo-controlled Phase III clinical study is aimed to assess the…
- Trial name
- NCT04487574
- Testing
- XC221
- Where
- 5 sites in Russia
- Volunteers
- 118 people
- Sponsor
- RSV Therapeutics LLC
Coronavirus Infection, COVID-19
WGS Analysis of COVID-19 Positive Patients
We aim to better understand the mode of action of COVID-19 in the context of its interaction with the host genome through whole-genome sequencing.
- Trial name
- NCT04353401
- Where
- United States
- Volunteers
- 79 people
- Sponsor
- Vanda Pharmaceuticals
Pneumococcal Vaccines
Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination
The study will evaluate the safety, tolerability, and immunogenicity of VAX-31 in adults ≥50 years of age.
- Trial name
- NCT07425392
- Testing
- 31-valent pneumococcal conjugate vaccine, PCV20
- Where
- 30 sites in United States
- Volunteers
- 752 people, healthy volunteers welcome
- Sponsor
- Vaxcyte, Inc.
Infection
Ciprofloxacin Special Drug Use Investigation - To Investigate the Safety and Efficacy in Patients With Ciprofloxacin iv Administration Without Dilution
This study is a post-marketing surveillance in Japan to investigate the safety especially focusing on injection site adverse events and efficacy in patients with Ciprofloxacin iv administration without dilution in the daily…
- Trial name
- NCT01690559
- Testing
- Cipro (Ciprofloxacin, BAYQ3939)
- Where
- Japan
- Volunteers
- 704 people
- Sponsor
- Bayer
Covid19
Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients.
An Adaptive, Randomized, Double-blind, Placebo-controlled study to examine the Effects of Tempol in subjects with COVID-19 infection.
- Trial name
- NCT04729595
- Testing
- Tempol
- Where
- 17 sites in United States
- Volunteers
- 248 people
- Sponsor
- Adamis Pharmaceuticals Corporation
Community-Acquired Infections, Bacterial Pneumonia
Study Comparing Tigecycline vs. Levofloxacin in Subjects Hospitalized With Community-Acquired Pneumonia
To compare the efficacy and safety of IV tigecycline to IV levofloxacin in the treatment of subjects with CAP requiring hospitalization.
- Conditions
- Community-Acquired Infections, Bacterial Pneumonia, Cross Infection
- Trial name
- NCT00081575
- Testing
- Tigecycline, Levofloxacin
- Volunteers
- 434 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
COVID-19 Infection
Extension Study in a Cohort of Adult Patients With COVID-19 Infection
The main objective of this study is to evaluate the incidence of post-COVID morbidity and characterize the complications profile in patients who participated in the APLICOV-PC study.
- Trial name
- E-APLICOV-PC (NCT05121740)
- Testing
- Plitidepsin 1.5 mg / day, Plitidepsin 2.0 mg / day, Plitidepsin 2.5 mg / day
- Where
- 10 sites in Spain
- Volunteers
- 34 people
- Sponsor
- PharmaMar
COVID-19, Lymphocytopenia
InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection ( ILIAD-7-US-I )
Comparison of the effects of CYT107 vs Placebo administered IM at 10μg/kg twice a week for three weeks on immune reconstitution of lymphopenic COVID-19 patients
- Trial name
- ILIAD-7-US-I (NCT04442178)
- Testing
- CYT107
- Where
- 5 sites in United States
- Volunteers
- 26 people
- Sponsor
- Revimmune
Long COVID
Study of LAU-7b for the Treatment of Long COVID in Adults
ESSOR is a double-blind, placebo-controlled study of the orally-administered antiviral and inflammation-controlling LAU-7b for the treatment of adults with Long COVID and moderate to severe symptoms.
- Trial name
- ESSOR (NCT05999435)
- Testing
- LAU-7b for 3 cycles
- Where
- 5 sites in Canada
- Volunteers
- 272 people
- Sponsor
- Laurent Pharmaceuticals Inc.
Covid19, SARS-CoV-2 Infection
A Trial of GC4419 in Patients With Critical Illness Due to COVID-19
A Trial of GC4419 in Patients with Critical Illness due to COVID-19
- Trial name
- NCT04555096
- Testing
- GC4419
- Where
- 3 sites in United States
- Volunteers
- 16 people
- Sponsor
- Galera Therapeutics, Inc.
SARS CoV 2 Infection
Phase II Study of AVX/COVID-12 Vaccine in Subjects With Prior SARS-CoV-2 Immunity Evidence
This is a Phase II study with single-blinded safety phase followed by double-blinded randomization, placebo-controlled, of administration of a single dose by two different administration routes (intramuscular route or intranasal…
- Trial name
- NCT05205746
- Testing
- Recombinant NDV Vectored Vaccine for SARS-CoV-2
- Where
- 4 sites in Mexico
- Volunteers
- 158 people, healthy volunteers welcome
- Sponsor
- Laboratorio Avi-Mex, S.A. de C.V.
SARS-CoV2 Infection
Efficacy and Safety of EXOSOME-MSC Therapy to Reduce Hyper-inflammation In Moderate COVID-19 Patients
In COVID-19 infection caused by the Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), there is a dysregulation of the immune system response that causes cytokine storm syndrome.
- Trial name
- EXOMSC-COV19 (NCT05216562)
- Testing
- Exosome-MSC Intravenous injection, COVID-19 Standard Treatment
- Where
- 3 sites in Indonesia
- Volunteers
- 60 people
- Sponsor
- Dermama Bioteknologi Laboratorium
COVID-19 Respiratory Infection, SARS-CoV-2 Acute Respiratory Disease
Photodynamic Therapy for COVID-19 Prevention
This is a single-center open-label study to evaluate antimicrobial photodynamic therapy (aPDT) for upper airway decolonization in patients presenting with SARS-CoV-2 positive antigen test with mild or no symptoms of COVID-19.
- Trial name
- NCT05184205
- Testing
- Nasal Photodisinfection
- Where
- Spain
- Volunteers
- 100 people
- Sponsor
- Ondine Biomedical Inc.
Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection, COVID-19
A Phase 2 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Patients With Multi-Site Pain Associated With Post-Acute Sequelae of SARS-CoV-2 Infection
This is a Phase 2, randomized, parallel-group, double-blind, placebo-controlled, 14-week study designed to evaluate the efficacy and safety of TNX-102 SL 5.6 mg (2 x 2.8 mg tablets) taken once daily at bedtime for the management…
- Conditions
- Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection, COVID-19, Long COVID, Long Haul COVID
- Trial name
- PREVAIL (NCT05472090)
- Testing
- TNX-102 SL
- Where
- 29 sites in United States
- Volunteers
- 63 people
- Sponsor
- Tonix Pharmaceuticals, Inc.
Pneumonitis, SARS-CoV Infection
GLS-1027 for the Prevention of Severe Pneumonitis Caused by SARS-CoV-2 Infection (COVID-19)
This clinical trial will evaluate the safety, tolerability and efficacy of GLS-1027 in the prevention of severe pneumonitis caused by SARS-CoV-2 infection
- Trial name
- NCT04590547
- Testing
- GLS-1027
- Where
- 17 sites in United States, Bulgaria and 3 more
- Volunteers
- 132 people
- Sponsor
- GeneOne Life Science, Inc.
SARS-CoV-2 Infection
Study of a Live rNDV Based Vaccine Against COVID-19
This is a Phase 1, open-label, non-randomized, dose-escalation study using three doses and two schemes of administration of a recombinant vaccine against SARS-CoV-2 based on a viral vector (Newcastle Disease virus) in 90 healthy…
- Trial name
- NCT04871737
- Testing
- Recombinant NDV Vectored Vaccine for SARS-CoV-2
- Where
- Mexico
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- Laboratorio Avi-Mex, S.A. de C.V.
Antibiotics Associated Colitis, Pulmonary Infection
Effect of Probiotic Lactobacilli (Lacidofil Cap®) for the Prevention of Antibiotic-Associated Diarrhea
Antibiotic-Associated Diarrhea (AAD) is a common complication of antibiotic use. The frequency of AAD can be high (26 - 60%) or moderate (13-29%) during hospital outbreaks and is relatively infrequent in outpatients.
- Trial name
- NCT01058356
- Where
- South Korea
- Volunteers
- 214 people
- Sponsor
- Pharmbio Korea Co., Ltd.